Keratosis Pilaris (KP): Treatment

General Principles

• KP often improves spontaneously over years, especially after adolescence
• Environmental humidity plays a role: many patients improve in summer or after moving to humid climates
• Patient education is key: any smoothing from topical or mechanical agents is temporary
• Therapies targeting the keratotic component frequently exacerbate the erythema, and vice versa

First-Line: Emollients & Keratolytics

Topical Retinoids

• Topical retinoids (e.g., tretinoin, adapalene) can reduce follicular hyperkeratosis in some patients
• Response is variable and not universal
• Topical calcipotriene (vitamin D analogue) has been reported effective in some patients

Addressing Erythema

• Pulsed dye laser (PDL, 585/595 nm) — targets perifollicular erythema; particularly useful for severe facial involvement (KP rubra)
• 810-nm diode laser — studied in a randomized clinical trial for KP treatment
• Low-potency topical corticosteroids may briefly reduce inflammation but are not recommended long term

Device-Based / Procedural Options

KP Atrophicans (Variants with Scarring)

• Emollients, corticosteroids, tretinoin, and keratolytics show no consistent benefit
• Systemic isotretinoin can stop progression and induce remission in some cases
• Dermabrasion, CO₂ laser, and 585-nm pulsed dye laser can improve the appearance of established atrophic scars
• Early treatment is important, as scarring is irreversible

Special Situations

• Associated atopic dermatitis / ichthyosis vulgaris: Treat underlying condition with moisturizers; may improve KP secondhand
• KP as drug side effect (e.g., RAF inhibitors): Consider dose adjustment if clinically significant
• KP in children: Reassurance and simple emollients are often sufficient; avoid over-treatment

What Does NOT Work

• No therapy consistently resolves both the keratotic texture and erythema simultaneously
• Topical corticosteroids are not recommended beyond short-term anti-inflammatory use
• No curative systemic agent exists for common KP (unlike KP atrophicans where isotretinoin may help)

Recent Evidence (2025 Systematic Review)

Keratosis Pilaris — Practical Treatment Formulation

Key principle: Treat in steps. Start with moisturization → add keratolysis → add retinoid if needed → consider laser for persistent erythema. Maintenance is indefinite — stopping treatment causes relapse.

STEP 1 — Baseline Moisturization (All Patients, Start Day 1)

STEP 2 — Keratolytic Agent (Add at Week 1–2 if texture is prominent)

Note: Ammonium lactate 12% lotion is the most widely used and evidence-supported keratolytic. Lactic acid and glycolic acid are preferred per the 2025 systematic review (Beyron, Eur J Dermatol, PMID 41277649).

STEP 3 — Topical Retinoid (Add at Week 4–6 if keratolytic alone is insufficient)

STEP 4 — Topical Calcipotriene (Alternative/Add-on, especially if erythema-dominant)

STEP 5 — Managing Erythema (When Redness is the Dominant Complaint)

Sample Full Prescription for a New Adult Patient (Mild–Moderate KP, Arms/Thighs)

1. Urea 20% cream — apply twice daily to affected arms and thighs after bathing
   (ongoing maintenance, indefinite)

2. Ammonium lactate 12% lotion — apply twice daily to same areas
   (start week 1; continue 8 weeks, then reassess)

3. If inadequate at week 6 → add Tretinoin 0.025% cream:
   - Weeks 1–2: apply every other night
   - Week 3 onward: apply every night
   - Review at 12 weeks

4. Sunscreen SPF 30+ on exposed areas daily (if using retinoid)

5. Avoid hot showers; use mild syndet cleanser; pat dry, do not rub

For KP with Prominent Erythema (KP Rubra / Facial)

1. Urea 10% cream — twice daily (gentler concentration for face)
2. Lactic acid 5% lotion — once daily at night
3. Calcipotriene 0.005% cream — twice daily if texture + erythema
4. Refer to dermatology for PDL or Nd:YAG laser if no improvement at 12 weeks

For KP Atrophicans (Scarring Variant)

1. Emollient (urea 10–20%) — twice daily, ongoing
2. Tretinoin 0.05% cream — once daily at night
3. Systemic isotretinoin (0.5 mg/kg/day) — if progressive; under dermatology supervision
   Duration: 4–6 months; reassess
4. Laser (CO₂ or PDL) — for established atrophic scars after active disease controlled

Monitoring & Review Timeline

Patient counselling point: KP cannot be cured. Any improvement is maintenance-dependent. Stopping treatment leads to relapse within weeks to months. Improvement typically takes 6–12 weeks to become visible.